Advertisement

Latest News

Iptacopan Reduces Proteinuria, Demonstrates Benefit in C3 Glomerulopathy

5 hours ago

In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.

Helen Colhoun, MD: Semaglutide 2.4 mg (Wegovy) Reduces Kidney Outcomes in SELECT

6 hours ago

Helen Colhoun, MD, discusses the results of a SELECT analysis she presented at the 61st European Renal Association Congress.

SELECT Analysis: Semaglutide 2.4 mg (Wegovy) Reduces Negative Kidney Outcomes

7 hours ago

Semaglutide 2.4 mg reduces kidney events in SELECT participants, showing renoprotective effects in addition to cardiovascular benefits.

Antinephrin Autoantibodies Could Aid in Predicting Disease Activity in Nephrotic Syndrome

23 hours ago

Circulating antinephrin autoantibodies identified as reliable biomarkers for MCD and primary FSGS, enhancing diagnostic precision and monitoring of nephrotic syndromes.

SGLT2 Inhibitors Can Improve Anemia in Patients with CKD

May 25, 2024

Data from ERA 24 builds on previous research examining the effect of SGLT2 inhibitors on hemoglobin levels among patients with chronic kidney disease.

Advertisement
Advertisement